Rima Nabbout, MD, PhD; Arun Mistry, MBChB, MRCP(UK), MRCPCH; Sameer Zuberi, MD; et al.
open access
JAMA Neurol. 2020;77(3):300-308. doi:10.1001/jamaneurol.2019.4113
This randomized clinical trial investigates whether fenfluramine reduced monthly convulsive seizure frequency relative to placebo in patients with Dravet syndrome who were already taking stiripentol-inclusive regimens.
Fernando. L. Pagan, MD; Michaeline L. Hebron, MS; Barbara Wilmarth, RN; et al.
open access
has audio
JAMA Neurol. 2020;77(3):309-317. doi:10.1001/jamaneurol.2019.4200
This randomized clinical trial evaluates the efficacy and safety of nilotinib hydrochloride for use in treatment of patients with Parkinson disease.
-
Audio Interview:
Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease
Johannes Kaesmacher, MD; Sebastian Bellwald, MD; Tomas Dobrocky, MD; et al.
JAMA Neurol. 2020;77(3):318-326. doi:10.1001/jamaneurol.2019.4192
This cohort study assesses whether administration of intra-arterial urokinase is safe and improves reperfusion among patients who have undergone failed or incomplete mechanical thrombectomy.
Kristen M. Krysko, MD, MAS; Alice Rutatangwa, DO, MSc; Jennifer Graves, MD, PhD, MAS; et al.
has active quiz
JAMA Neurol. 2020;77(3):327-338. doi:10.1001/jamaneurol.2019.4173
This systematic review and meta-analysis examines the occurrence of multiple sclerosis relapses in women who are breastfeeding
Yoann Launey, PhD; Tim D. Fryer, PhD; Young T. Hong, PhD; et al.
open access
has active quiz
JAMA Neurol. 2020;77(3):339-349. doi:10.1001/jamaneurol.2019.3854
This single-center observational cohort study aims to comprehensively characterize the spatiotemporal changes in cerebral physiology after traumatic brain injury by comparing a cohort of affected patients with healthy control participants.
Rebecca F. Gottesman, MD, PhD; Thomas H. Mosley, PhD; David S. Knopman, MD; et al.
JAMA Neurol. 2020;77(3):350-357. doi:10.1001/jamaneurol.2019.4339
This cross-sectional study examines the association between intracranial atherosclerotic disease and cerebral β-amyloid deposition in adults without dementia enrolled in the Atherosclerosis Risk in Communities Study.
Andy J. Liu, MD; Adam M. Staffaroni, PhD; Julio C. Rojas-Martinez, MD, PhD; et al.
JAMA Neurol. 2020;77(3):358-366. doi:10.1001/jamaneurol.2019.4284
This study investigates the potential association between tuberous sclerosis–associated neuropsychiatric disorders and frontotemporal dementia.
Stella A. Glasmacher, BMBS, MRes; Charis Wong, MBChB; Iona E. Pearson, BMedSci; et al.
JAMA Neurol. 2020;77(3):367-376. doi:10.1001/jamaneurol.2019.3924
This systematic review and meta-analysis examines prognostic factors in c9 amyotrophic lateral sclerosis, c9 frontotemporal dementia, c9 amyotrophic lateral sclerosis and frontotemporal dementia, and atypical phenotypes.
Edwin Jabbari, MRCP; Negin Holland, MRCP; Viorica Chelban, MRCP; et al.
open access
JAMA Neurol. 2020;77(3):377-387. doi:10.1001/jamaneurol.2019.4347
This cohort study defines the distinguishing features of progressive supranuclear palsy and corticobasal syndrome and assesses their usefulness in facilitating early diagnosis and separation from Parkinson disease among patients with atypical parkinsonian syndromes.